The EU's Critical Medicines Act, a bold initiative to secure healthcare resilience, has emerged from the crucible of negotiations, albeit with a few compromises. This legislation, aimed at reducing Europe's reliance on external drug suppliers, particularly China and India, has been a long-time coming. The urgency of the matter is underscored by the recurring drug shortages and escalating trade tensions with the US.
One of the key sticking points was the issue of stockpiling. The European Parliament, led by Tomislav Sokol, advocated for mandatory sharing of medicine reserves among EU states during crises, along with the creation of a bloc-wide stockpile and a dedicated medicines security fund. However, EU governments, wary of encroaching on national competences, resisted binding obligations. The final compromise, while not mandating sharing, commits countries to exchanging information on contingency stocks and coordinating stockpiling efforts. This approach ensures that stockpiling in one country doesn't inadvertently create shortages in another, a point emphasized by Socialist MEP Tiemo Wölken.
Another contentious issue was the public procurement rules for critical medicines. The Parliament had proposed a 50% sourcing requirement from within the EU for suppliers, a measure opposed by the pharmaceutical industry and trade-reliant states. The final text, while still favoring domestic manufacturing, drops the fixed target in favor of a scoring system that gives preference to suppliers with greater production capacity in Europe. This approach, as Sokol noted, sends a clear signal that Europe is committed to strengthening its pharmaceutical manufacturing base.
The legislation also reforms public procurement rules, expanding the scope for joint purchasing. This mechanism is designed to strengthen the negotiating power of smaller states with pharmaceutical companies. Countries will be able to jointly buy critical medicines through expanded EU procurement schemes, with the requirement that at least five countries initiate the process. However, only the Commission can launch it.
The law also creates a framework for 'strategic projects' aimed at expanding pharmaceutical manufacturing capacity closer to the EU's borders. Negotiators agreed to accelerate permitting procedures for these projects, but rejected Parliament's attempt to broaden support to a wider range of medicines. Member states also pushed for more flexible language on future EU financing, avoiding commitments that could complicate negotiations over the bloc's next long-term budget for 2028-2034.
Despite the compromises, the agreement marks an early political victory for Health Commissioner Olivér Várhelyi, who fast-tracked the legislation within his first 100 days in office. However, the provisional agreement still requires formal approval from capitals and the European Parliament.
In my opinion, the Critical Medicines Act is a necessary step towards securing Europe's healthcare resilience. While the compromises made may have watered down some of the original ambition, the legislation still represents a significant step forward. The EU's commitment to diversifying supply chains and boosting domestic production capacity is a welcome development, particularly in light of the ongoing trade tensions with the US. However, the question remains: will these measures be enough to prevent future drug shortages and ensure Europe's healthcare security?
